A Phase IV, Randomised, Multi-centre, Efficacy and Safety Study Examining the Effect of Induction Dosing with the combination of peginterferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Infected with Hepatitis C Genotype 1.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CHARIOT
- Sponsors Roche
- 06 May 2016 Time frame of primary end point changed from week 42 to week 72.
- 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry record ACTRN12605000488606).
- 13 May 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.